144 related articles for article (PubMed ID: 22784361)
1. Intra-articular injection of mesenchymal stem cells expressing coagulation factor ameliorates hemophilic arthropathy in factor VIII-deficient mice.
Kashiwakura Y; Ohmori T; Mimuro J; Yasumoto A; Ishiwata A; Sakata A; Madoiwa S; Inoue M; Hasegawa M; Ozawa K; Sakata Y
J Thromb Haemost; 2012 Sep; 10(9):1802-13. PubMed ID: 22784361
[TBL] [Abstract][Full Text] [Related]
2. Safety of intra-articular transplantation of lentivirally transduced mesenchymal stromal cells for haemophilic arthropathy in a non-human primate.
Ohmori T; Mizukami H; Katakai Y; Kawai S; Nakamura H; Inoue M; Shu T; Sugimoto H; Sakata Y
Int J Hematol; 2018 Sep; 108(3):239-245. PubMed ID: 29737459
[TBL] [Abstract][Full Text] [Related]
3. In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A.
Hemşinlioğlu C; Aslan ES; Taştan C; Çakırsoy D; Turan RD; Seyis U; Elek M; Sır Karakuş G; Günaydın ÖS; Abanuz S; Kançağı DD; Yurtsever B; Yalçın K; Kasap M; Ovalı E
Turk J Haematol; 2023 May; 40(2):118-124. PubMed ID: 37022209
[TBL] [Abstract][Full Text] [Related]
4. Ectopic Expression of FVIII in HPCs and MSCs Derived from hiPSCs with Site-Specific Integration of
Zhao J; Zhou M; Wang Z; Wu L; Hu Z; Liang D
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054807
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
[TBL] [Abstract][Full Text] [Related]
6. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
Wyseure T; Yang T; Zhou JY; Cooke EJ; Wanko B; Olmer M; Agashe R; Morodomi Y; Behrendt N; Lotz M; Morser J; von Drygalski A; Mosnier LO
JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465300
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
[TBL] [Abstract][Full Text] [Related]
8. In Utero Transplantation of Placenta-Derived Mesenchymal Stromal Cells for Potential Fetal Treatment of Hemophilia A.
Kumar P; Gao K; Wang C; Pivetti C; Lankford L; Farmer D; Wang A
Cell Transplant; 2018 Jan; 27(1):130-139. PubMed ID: 29562772
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
[TBL] [Abstract][Full Text] [Related]
10. Expression of human coagulation factor VIII in adipocytes transduced with the simian immunodeficiency virus agmTYO1-based vector for hemophilia A gene therapy.
Ogata K; Mimuro J; Kikuchi J; Tabata T; Ueda Y; Naito M; Madoiwa S; Takano K; Hasegawa M; Ozawa K; Sakata Y
Gene Ther; 2004 Feb; 11(3):253-9. PubMed ID: 14737084
[TBL] [Abstract][Full Text] [Related]
11. Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia.
Doering CB
Methods Mol Biol; 2008; 433():203-12. PubMed ID: 18679625
[TBL] [Abstract][Full Text] [Related]
12. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
[TBL] [Abstract][Full Text] [Related]
13. Altered collagen turnover in factor VIII-deficient rats with hemophilic arthropathy identifies potential novel serological biomarkers in hemophilia.
Manon-Jensen T; Karsdal MA; Nielsen LN; Kjelgaard-Hansen M; Vandahl B; Olsen EH; Enoksson M; Roepstorff K
J Thromb Haemost; 2016 Dec; 14(12):2419-2429. PubMed ID: 27681457
[TBL] [Abstract][Full Text] [Related]
14. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
16. Efficient production of human FVIII in hemophilic mice using lentiviral vectors.
Kootstra NA; Matsumura R; Verma IM
Mol Ther; 2003 May; 7(5 Pt 1):623-31. PubMed ID: 12718905
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
18. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
[TBL] [Abstract][Full Text] [Related]
19. Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice.
Bunting S; Zhang L; Xie L; Bullens S; Mahimkar R; Fong S; Sandza K; Harmon D; Yates B; Handyside B; Sihn CR; Galicia N; Tsuruda L; O'Neill CA; Bagri A; Colosi P; Long S; Vehar G; Carter B
Mol Ther; 2018 Feb; 26(2):496-509. PubMed ID: 29292164
[TBL] [Abstract][Full Text] [Related]
20. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
